Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol 2009 ; 10 : 223.
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 ; 355 : 1456.
Jang JH, Harada H, Shibayama H, et al. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low-or intermediate-1 risk myelodysplastic syndromes. Int J Hematol 2015 ; 102 : 401.
Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML : a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood 2020 ; 136 : 674.
Kantarjian H, Issa JJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes : results of a phase III randomized study. Cancer 2006 ; 106 : 1794.